Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223–243 (1997).

Article  CAS  PubMed  Google Scholar 

Marrack, P., Kappler, J. & Kotzin, B. L. Autoimmune disease: why and where it occurs. Nat. Med. 7, 899–905 (2001).

Article  CAS  PubMed  Google Scholar 

Cox, D. B., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S. & Gregory, P. D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636–646 (2010).

Article  CAS  PubMed  Google Scholar 

Bogdanove, A. J. & Voytas, D. F. TAL effectors: customizable proteins for DNA targeting. Science 333, 1843–1846 (2011).

Article  CAS  PubMed  Google Scholar 

Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281–2308 (2013).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo, C., Ma, X., Gao, F. & Guo, Y. Off-target effects in CRISPR/Cas9 gene editing. Front. Bioeng. Biotechnol. 11, 1143157 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Kouranova, E. et al. CRISPRs for optimal targeting: delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos. Hum. Gene Ther. 27, 464–475 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar, R. et al. Polymeric delivery of therapeutic nucleic acids. Chem. Rev. 121, 11527–11652 (2021).

Article  CAS  PubMed  Google Scholar 

Sahel, D. K. et al. CRISPR/Cas9 genome editing for tissue-specific in vivo targeting: nanomaterials and translational perspective. Adv. Sci. 10, e2305072 (2023).

Article  Google Scholar 

Pesch, T. et al. Molecular design, optimization, and genomic integration of chimeric B cell receptors in murine B cells. Front. Immunol. 10, 2630 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang, Y. A.-O., Wang, D., Lü, P., Ma, S. & Chen, K. Research progress on nucleic acid detection and genome editing of CRISPR/Cas12 system. Mol. Biol. Rep. 50, 3723–3738 (2019).

Article  Google Scholar 

Senthilnathan, R. A.-O. X. et al. An update on CRISPR-Cas12 as a versatile tool in genome editing. Mol. Biol. Rep. 50, 2865–2881 (2019).

Article  Google Scholar 

Liu, H., Zhu, Y., Li, M. & Gu, Z. A.-O. Precise genome editing with base editors. Med. Rev. 22, 75–84 (2019).

Google Scholar 

Doman, J. L., Sousa, A. A., Randolph, P. B., Chen, P. J. & Liu, D. R. Designing and executing prime editing experiments in mammalian cells. Nat. Protoc. 17, 2431–2468 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhao, Z., Shang, P., Mohanraju, P. & Geijsen, N. Prime editing: advances and therapeutic applications. Trends Biotechnol. 41, 1000–1012 (2022).

Article  Google Scholar 

Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome manipulation. Nat. Rev. Genet. 24, 161–177 (2023).

Article  CAS  PubMed  Google Scholar 

Zhou, T. et al. Lupus enhancer risk variant causes dysregulation of IRF8 through cooperative lncRNA and DNA methylation machinery. Nat. Commun. 13, 1855 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhowmik, R. & Chaubey, B. CRISPR/Cas9: a tool to eradicate HIV-1. AIDS Res. Ther. 19, 58 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Stefanoudakis, D. et al. The potential revolution of cancer treatment with CRISPR technology. Cancers 15, 1813 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Legut, M., Dolton, G., Mian, A. A., Ottmann, O. G. & Sewell, A. K. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood 131, 311–322 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ray, M. et al. CRISPRed macrophages for cell-based cancer immunotherapy. Bioconjug. Chem. 29, 445–450 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu, C. et al. Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases. Nat. Commun. 9, 4092 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Limanskiy, V., Vyas, A., Chaturvedi, L. S. & Vyas, D. Harnessing the potential of gene editing technology using CRISPR in inflammatory bowel disease. World J. Gastroenterol. 25, 2177–2187 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bevacqua, R. J. et al. CRISPR-based genome editing in primary human pancreatic islet cells. Nat. Commun. 12, 2397 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baker, C. & Hayden, M. S. Gene editing in dermatology: harnessing CRISPR for the treatment of cutaneous disease. F1000Res. 9, 281 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin, W. et al. Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation. Nat. Commun. 14, 265 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Levy, E. C., J., Reger, R., Allan, D. & Childs, R. RNA-seq analysis reveals CCR5 as a key target for CRISPR gene editing to regulate in vivo NK cell trafficking. Cancers 13, 872 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo, X. et al. CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy. J. Immunother. Cancer 9, e001975 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Greiner, V. et al. CRISPR-mediated editing of the B cell receptor in primary human B cells. iScience 12, 369–378 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang, H. et al. CRISPR/Cas9-mediated gene editing in human iPSC-derived macrophage reveals lysosomal acid lipase function in human macrophages — brief report. Arterioscler. Thromb. Vasc. Biol. 37, 2156–2160 (2017).

Article